Skip to main content
September 26, 2019

BERKELEY, CA – September 26, 2019 –  On September 19, 2019, a three-member JAMS panel issued an Interim Award in the arbitration between Intellia Therapeutics, Inc. (Intellia) and Caribou Biosciences, Inc. (Caribou). On October 17, 2018, Intellia initiated an arbitration proceeding with JAMS asserting that Caribou was violating the terms and conditions of the license agreement between Caribou and Intellia as it related to certain disputed technology in a defined field of human therapeutics.

February 12, 2019

BERKELEY, CA – February 12, 2019 – Caribou Biosciences, Inc., a leading CRISPR genome editing company, announced today that it has expanded its Scientific Advisory Board (SAB) with the appointment of six new members: Emily Balskus, PhD; Ami Bhatt, MD, PhD; Dean Lee, MD, PhD; Jeffrey Rathmell, PhD; Noopur Raje, MD; and Cameron Turtle, MBBS, PhD. The newly appointed members will work with current SAB members and Caribou co-founders Jennifer Doudna, PhD and Martin Jinek, PhD.

December 12, 2018

BERKELEY, CA – December 12, 2018 – Caribou Biosciences, Inc., a leading genome editing company, announced today that it has appointed Natalie Sacks, MD to its Board of Directors. Dr. Sacks is an accomplished industry leader and oncology expert who has played a key role in the development and approval of several oncology therapeutics. 

September 10, 2018
The interference proceeding remains terminated without any determination of inventorship on CRISPR/Cas9 genome editing technology or its application to eukaryotic cells   University of California/University of Vienna/Dr. Charpentier have patent applications covering the use of CRISPR/Cas9 genome editing technology in all environments that do not interfere with the Broad’s patent claims in this proceeding